Tumor suppressor RKIP inhibits prostate cancer cell metastasis and sensitizes prostate cancer cells to docetaxel treatment.

Zhu, C X; Li, W Z; Guo, Y L; Chen, L; Li, G H; Yu, J J; Shu, B; Peng, S

Zhu, C X; Li, W Z; Guo, Y L; Chen, L; Li, G H; Yu, J J; Shu, B; Peng, S.

Neoplasma ; 65(2): 228-233, 2018.

Article in En | MEDLINE | ID: mdl-29534584

Subject(s)

Docetaxel/pharmacology; Neoplasm Metastasis; Phosphatidylethanolamine Binding Protein/metabolism; Prostatic Neoplasms/pathology; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Humans; Male; Phosphatidylethanolamine Binding Protein/genetics; Prostatic Neoplasms/drug therapy; Signal Transduction

Key words

RKIP; docetaxel treatment inhibition.; prostate cancer

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Phosphatidylethanolamine Binding Protein / Docetaxel / Neoplasm Metastasis Limits: Humans / Male Language: En Journal: Neoplasma Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google